MARKET

BMRA

BMRA

Biomerica Inc
NASDAQ
3.920
+0.170
+4.53%
Pre Market: 4.200 +0.28 +7.14% 08:32 09/29 EDT
OPEN
3.770
PREV CLOSE
3.750
HIGH
3.970
LOW
3.740
VOLUME
108.86K
TURNOVER
--
52 WEEK HIGH
7.38
52 WEEK LOW
2.560
MARKET CAP
52.50M
P/E (TTM)
-10.9375
1D
5D
1M
3M
1Y
5Y
Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test
Biomerica (NASDAQ:BMRA) on Thursday said its Aware Breast Self Ex...
Seekingalpha · 4h ago
Biomerica's Aware Breast Self Exam and EZ Detect Colon Disease Test Now Available On Amazon And Fulfilled By Amazon
 Biomerica, Inc. (NASDAQ:BMRA) (the "Company") today announced that the Company's Aware® Breast Self Exam device and EZ Detect Colon Disease test are now being sold on Amazon and fulfilled by
Benzinga · 5h ago
Bright Minds, PaxMedica top healthcare gainers; PolyPid, Shuttle lead losers' pack
Gainers: Bright Minds Biosciences (DRUG) +40%. PaxM...
Seekingalpha · 09/02 14:05
We're Interested To See How Biomerica (NASDAQ:BMRA) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 08/31 10:25
BRIEF-Biomerica To Launch Infoods IBS Test
BRIEF-Biomerica To Launch Infoods IBS Test
Reuters · 08/30 12:22
Biomerica Plans Launch Of InFoods IBS Test
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022   Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development
Benzinga · 08/30 12:21
Biomerica to Launch Irritable Bowel Syndrome Test Before 2022-End; Shares Rise
Biomerica to Launch Irritable Bowel Syndrome Test Before 2022-End; Shares Rise
MT Newswires · 08/30 10:38
BRIEF-Biomerica Reports Fiscal 2022 Year End Results
BRIEF-Biomerica Reports Fiscal 2022 Year End Results
Reuters · 08/29 21:03
More
About BMRA
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. The Company's products are used at the point-of-care in home and in physicians' offices and in hospital/clinical laboratories for detection and treatment of medical conditions and diseases. The Company also engages in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company’s diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications. The Company’s medical diagnostic products are sold primarily in two markets: clinical laboratories and point-of-care.

Webull offers kinds of Biomerica Inc stock information, including NASDAQ:BMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRA stock methods without spending real money on the virtual paper trading platform.